Please login to the form below

Not currently logged in
Email:
Password:

GSK trials shingles vaccine

GlaxoSmithKline has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles

GlaxoSmithKline (GSK) has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles.

The phase III clinical programme will study more than 30,000 patients worldwide and will evaluate the efficacy, safety and immunogenicity of the vaccine.

Norman Begg, chief medical officer of GSK Biologicals said: "The commencement of the phase III programme for our candidate's herpes zoster vaccine is a significant milestone. Shingles is an often debilitating condition for which there are limited treatment and prevention options.

"Progression into late-stage development of our herpes zoster vaccine is an important milestone in ongoing efforts to potentially help address an important unmet need," he added.

Herpes zoster is commonly known as shingles. It is caused by the varicella-zoster virus (VZV) and occurs in around 3 out of 1,000 people per year in Europe.

24th August 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics